This inventor holds 4 USPTO granted patents and 16 published patent applications and 1 EPO patent. Top assignees: Chinese Academy of Sciences, Fca US LLC, Jiangsu Huaiyu Pharmaceutical Co., Ltd.. Active years: 2024-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2024-2026
Title: Discovering the Innovations of Yan Liu
Introduction
Yan Liu is a prominent inventor based in Shanghai, China, recognized for his significant contributions to the field of biotechnology. With one remarkable patent to his name, Liu has demonstrated his dedication to advancing medical treatments and therapeutic methods.
Latest Patents
Liu's most notable patent is titled "SEMA4D antibody, preparation method therefor and use thereof." This innovation revolves around a murine or fully human monoclonal antibody that specifically targets the SEMA4D antigen. The antibody is not only a breakthrough in antibody technology but also possesses activities aimed at combating tumors, showcasing potential therapeutic applications for cancer treatment.
Career Highlights
Currently, Yan Liu is a key member of Jiangsu Huaiyu Pharmaceutical Co., Ltd., where he applies his expertise in the development of innovative pharmaceutical solutions. His focus on antibody research demonstrates his commitment to enhancing medical therapies and patient outcomes.
Collaborations
Throughout his career, Liu has collaborated with talented professionals, including coworkers Yingying Hu and Xiaodan Cao. These partnerships play an essential role in fostering creativity and facilitating advanced research projects in the pharmaceutical sector.
Conclusion
Yan Liu's contributions to the field of biotechnology, particularly with his SEMA4D antibody patent, highlight the impact of innovative thinking in the medical arena. His ongoing work at Jiangsu Huaiyu Pharmaceutical Co., Ltd. and collaborations with skilled colleagues underscore a promising future for developments in cancer therapy and treatment methodologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile